Clinical Trial Update: Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). [Phase 2]

View source ↗

Summary

Phase II open-label, multicenter trial (MONET) completed comparing PF-04523655 to Lucentis for neovascular age-related macular degeneration due to CNV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• PF-04523655

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Age Related Macular Degeneration | Phase 2 | Status: COMPLETED